Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Hematology

Long-Term Monitoring and Survivorship

At a Glance

Classic Hairy Cell Leukemia (HCL) requires lifelong monitoring through regular blood tests and clinic visits. While survivors typically enjoy a near-normal life expectancy, ongoing care is essential to watch for signs of relapse, manage immune system weakness, and screen for second cancers.

Finishing treatment for Classic Hairy Cell Leukemia (HCL) is a major milestone, but it is also the beginning of a new phase: survivorship. Because HCL is a chronic condition, you will remain in a long-term relationship with your hematology team [1]. The goal of this phase is to maintain your remission, monitor for the disease’s return, and ensure your overall long-term health [2].

Your Monitoring Schedule

While every clinic is different, most specialists use a tapering schedule for check-ups. If your blood counts remain stable and you feel well, the time between visits will gradually increase [1][3].

Time Since Treatment Typical Frequency of CBC & Clinic Visits Primary Focus of the Visit
Year 1 Every 3 to 6 months Monitoring recovery of blood counts (ANC, Hgb, Platelets).
Years 2–5 Every 6 to 12 months Watching for early signs of relapse or late side effects.
Year 5+ Annually Long-term wellness and screening for other health issues.

Understanding “Lab Anxiety”

It is completely normal to feel a surge of worry before a scheduled blood test—a phenomenon often called “scanxiety” or “lab anxiety.” Remember that HCL is a very slow-growing disease [4]. Even if your counts begin to shift, it does not mean you are in immediate danger; it simply gives your doctor the information they need to plan the next steps well in advance [5].

Managing the Risk of Relapse

Many patients achieve remissions that last for decades, but HCL can return [6][7]. Relapse is not a failure of your first treatment; it is simply the nature of the disease for some people [1].

Signs to call your doctor between visits include:

  • A return of significant, unexplained fatigue [8].
  • Recurrent infections or fevers that won’t go away [9].
  • A feeling of fullness or pain in the upper left side of your abdomen (spleen area) [8].
  • New or unusual bruising or bleeding [8].

Long-Term Health and Second Malignancies

Survivors of HCL generally enjoy a near-normal life expectancy [10]. However, having HCL (and the treatments used to manage it) can affect your health in two specific ways:

  1. Prolonged Immunosuppression: Treatments like cladribine can lower your T-cells for a year or more after treatment [11]. This means you may stay more vulnerable to certain infections and may have a weaker response to vaccines like the flu or COVID-19 shots [12].
  2. Second Malignancies: HCL survivors have a slightly higher risk of developing a second, unrelated type of cancer, such as skin cancer or other solid tumors [10]. Regular physicals and age-appropriate screenings (like colonoscopies or dermatology exams) are a vital part of your care.

Despite the need for ongoing monitoring, most HCL survivors live full, active lives, returning to work, family, and the activities they enjoyed before their diagnosis [10].

Common questions in this guide

How often will I need blood tests after HCL treatment?
In the first year after treatment, you will likely need a complete blood count (CBC) every 3 to 6 months. As your blood counts stabilize over time, these check-ups may decrease to every 6 to 12 months, and eventually become annual visits.
What are the warning signs that hairy cell leukemia is coming back?
Signs of an HCL relapse include severe unexplained fatigue, frequent infections or fevers, unusual bruising, and a feeling of fullness or pain in the upper left side of your abdomen near your spleen.
Will I have a normal life expectancy after surviving HCL?
Yes, survivors of classic hairy cell leukemia generally enjoy a near-normal life expectancy. Most people are able to return to work, family, and their usual active lives while continuing with their routine monitoring.
Why is my immune system still weak long after HCL treatment?
Treatments like cladribine can lower your T-cells, causing prolonged immunosuppression for a year or more after treatment. This means you may remain more vulnerable to certain infections and might not respond as strongly to standard vaccines.
Am I at risk for getting other types of cancer after having HCL?
HCL survivors have a slightly higher risk of developing a second, unrelated cancer, such as skin cancer or other solid tumors. Regular physical exams and age-appropriate screenings, like dermatology exams and colonoscopies, are a vital part of your long-term care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific blood counts (like ANC, hemoglobin, or LDH) are you watching most closely during my follow-up visits?
  2. 2.How often do I need a physical exam to check the size of my spleen?
  3. 3.Should we consider testing for Minimal Residual Disease (MRD), and how will those results change my monitoring plan?
  4. 4.Am I at an increased risk for other types of cancer, and what screenings (like dermatology exams) should I prioritize?
  5. 5.Is my immune system still considered 'suppressed' from my treatment, and should I be revaccinated for certain illnesses?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Treatment of hairy cell leukemia.

    Chihara D, Kreitman RJ

    Expert review of hematology 2020; (13(10)):1107-1117 doi:10.1080/17474086.2020.1819231.

    PMID: 32893700
  2. 2

    Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group.

    Paillassa J, Maitre E, Belarbi Boudjerra N, et al.

    Cancers 2024; (16(12)) doi:10.3390/cancers16122185.

    PMID: 38927891
  3. 3

    Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.

    Grever M, Andritsos L, Banerji V, et al.

    Leukemia 2021; (35(7)):1864-1872 doi:10.1038/s41375-021-01257-7.

    PMID: 33947938
  4. 4

    Patients with relapsed/refractory hairy-cell leukemia.

    Paillassa J, Troussard X

    Cancer reports (Hoboken, N.J.) 2022; (5(3)):e1495 doi:10.1002/cnr2.1495.

    PMID: 34250762
  5. 5

    Lytic Bone Lesion: An Unusual Presentation of Hairy Cell Leukemia.

    Fasulo SM, Narvaneni S, Kumar V, et al.

    Cureus 2021; (13(1)):e12959 doi:10.7759/cureus.12959.

    PMID: 33659114
  6. 6

    Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.

    Benz R, Arn K, Andres M, et al.

    Blood advances 2020; (4(15)):3699-3707 doi:10.1182/bloodadvances.2020002160.

    PMID: 32777066
  7. 7

    Outcome of hairy cell leukemia patients treated with cladribine - a 10-year single-center experience in Pakistan.

    Zahid MF, Mehdi MQ, Ali N

    Hematology, transfusion and cell therapy 2019; (41(2)):134-138 doi:10.1016/j.htct.2018.08.006.

    PMID: 31084763
  8. 8

    Classic hairy cell leukemia with an aggressive presentation.

    Fugere T, Harley S, Godbole A

    Proceedings (Baylor University. Medical Center) 2021; (34(6)):721-723 doi:10.1080/08998280.2021.1934344.

    PMID: 34733001
  9. 9

    Concomitantly Diagnosed Disseminated M kansasii Infection and Hairy Cell Leukemia With Review of Pathophysiology.

    Stanton DJ, Quadri NZ, Tanabe MB

    Journal of investigative medicine high impact case reports 2024; (12()):23247096241253343 doi:10.1177/23247096241253343.

    PMID: 38767131
  10. 10

    Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.

    Paillassa J, Cornet E, Noel S, et al.

    Blood cancer journal 2020; (10(5)):62 doi:10.1038/s41408-020-0328-z.

    PMID: 32461544
  11. 11

    Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands.

    Dinmohamed AG, Posthuma EFM, Visser O, et al.

    Blood 2018; (131(12)):1380-1383 doi:10.1182/blood-2017-12-820381.

    PMID: 29382643
  12. 12

    Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2.

    Annunzio K, Ozga M, Huang Y, et al.

    EJHaem 2023; (4(4)):1200-1202 doi:10.1002/jha2.764.

    PMID: 38024604

This page is for informational purposes only and explains survivorship after HCL treatment. Always consult your hematology team for specific medical advice and monitoring schedules.

Get notified when new evidence is published on Classic hairy cell leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.